Valproate, weight gain and carbohydrate craving: a gender study

Area of Science:

• Neurology
• Endocrinology
• Metabolic Disorders

Background:

• Valproic acid (VPA) is a widely used antiepileptic drug.
• Weight gain is a known side effect of VPA therapy.
• Gender-specific differences in VPA's metabolic effects are not fully understood.

Purpose of the Study:

• To compare weight gain incidence and magnitude between male and female epilepsy patients on VPA monotherapy.
• To investigate gender-specific differences in carbohydrate craving, body composition, glucose, and lipid metabolism during VPA therapy.

Main Methods:

• Prospective study of 106 epilepsy patients on VPA monotherapy.
• Assessment of weight changes, carbohydrate craving, and sociopsychological factors.
• Measurement of body composition, glucose, lipid profiles, leptin, insulin, CRP, and TNF-alpha.

Main Results:

• Significant weight gain observed in both genders, more pronounced in women.
• Women showed higher leptin levels, HDL-cholesterol, and lower triglycerides.
• Carbohydrate craving and weight gain-related sociopsychological issues were more frequent in women.

Conclusions:

• Women are more susceptible to weight gain during VPA therapy.
• Leptin resistance and increased carbohydrate craving may contribute to VPA-induced weight gain in women.
• Gender-specific approaches may be needed for managing VPA therapy.